Search clinical trials for: Ramucirumab - IV

Total 3333 results

Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) in Healthy Participants

Healthy

United States
Shanghai Henlius Biotech

Terminated

Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult Subjects

Healthy Male Volunteers

China
Yonsei University

Not yet recruiting

An Open Label, Single-arm, Multicenter Phase Ib/II Study to Evaluate the Safety and Efficacy of T-Dxd in Combination With Ramucirumab as a 2nd Line in Patients With HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gastric Cancer | Gastroesophageal Junction (GEJ) Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers

Gastric Cancer | Non-small Cell Lung Cancer | Colo-rectal Cancer

China
Eli Lilly and Company
Parexel

Completed

Study of IMC-1121B in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer

Breast Cancer

United States
Yale University

Withdrawn

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Transitional Cell Carcinoma

United States
Samsung Medical Center

Recruiting

Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

Gastric Cancer

Korea, Republic of
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH)

Hepatocellular Carcinoma

United States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Eli Lilly and Company

Completed

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Adult Glioblastoma Multiforme

United States
Eli Lilly and Company

Completed

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

Hepatocellular Carcinoma

United States
Baylor Research Institute

Not yet recruiting

Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Esophageal Adenocarcinoma

United States
Hellenic Cooperative Oncology Group
Eli Lilly and Company; Celgene Corporation

Completed

RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma (RACING)

Pancreatic Adenocarcinoma

Greece
Eli Lilly and Company

Terminated

A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

Advanced Solid Tumor

United States, Japan
Tianjin Medical University Cancer Institute and...

Recruiting

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

China
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company

Recruiting

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Non Small Cell Lung Cancer | Metastatic | Recurrent

United States
Eli Lilly and Company

Completed

Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

Breast Cancer

United States, Canada
Eli Lilly and Company

No longer available

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Metastatic Gastric Cancer | Metastatic Adenocarcinoma of the Gastroesophageal Junction

Germany, Netherlands, Austria, Greece, Korea, Republic of
Eli Lilly and Company

Completed

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Breast Cancer

United States, Canada, Australia, Belgium, Brazil, Croatia, Czechia, Egypt, Germany, Ireland, Israel, Korea, Republic of, Lebanon, New Zealand, Peru, Poland, Russian Federation, Serbia, Slovakia, South Africa, Spain, Taiwan, United...
Eli Lilly and Company

Completed

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Adenocarcinoma | Gastric Cancer

United States, Canada, Brazil, Czechia, Egypt, Korea, Republic of, Lebanon, Poland, Russian Federation, Spain, Romania, United Kingdom, Australia, Croatia, Italy, Philippines, Thailand, Argentina, Bosnia and Herzegovina, Chile, ... and more
Walid Shaib, MD
Eli Lilly and Company; Hoosier Cancer Research Network

Active, not recruiting

Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Eli Lilly and Company

Completed

A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Poland, Romania, Hungary, Russian Federation, Australia, France, Argentina, United Kingdom, New Zealand, Turkey, Slovakia
Liza Villaruz, MD

Completed

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Eli Lilly and Company

Completed

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Malignant Solid Tumor

United States
Institut für Klinische Krebsforschung IKF GmbH...
Eli Lilly and Company; Trium Analysis Online GmbH

Active, not recruiting

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (RAMTAS)

Colorectal Cancer

Germany
Eli Lilly and Company

Completed

Study of Ramucirumab in Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

United States, United Kingdom
Eli Lilly and Company

Completed

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Metastatic Malignant Melanoma

United States
ROGER S KERESZTES MD

Terminated

Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy

Carcinoma, Non-Small-Cell Lung

United States
Eli Lilly and Company
Children's Oncology Group

Completed

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Recurrent Tumor | Pediatric Solid Tumor | Refractory Tumor | CNS Malignancies

United States
Eli Lilly and Company

Completed

Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas

Adenocarcinoma

Japan
Institut für Klinische Krebsforschung IKF GmbH...

Completed

Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction (RE-ExPEL)

Gastric Adenocarcinoma | Metastatic Adenocarcinoma of the Gastroesophageal Junction

Germany
Eli Lilly and Company

Completed

A Study in Participants With Advanced Solid Tumors

Solid Tumor

China
Eli Lilly and Company

Completed

Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy

Advanced Solid Tumors

United States
Sanofi

Active, not recruiting

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer (CARMEN-GC01)

Adenocarcinoma Gastric | Gastrooesophageal Cancer

Japan, Belgium, Korea, Republic of, Spain, Russian Federation, Turkey
Eli Lilly and Company

Completed

A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma (RAINBOW)

Gastric Cancer

United States, Australia, Belgium, Korea, Republic of, Russian Federation, Germany, Poland, Spain, Argentina, Austria, Brazil, Bulgaria, Chile, Estonia, France, Hungary, Israel, Italy, Japan, Lithuania, Mexico, Portugal, Romania, Sing... and more
National Health Research Institutes, Taiwan
China Medical University Hospital; Chang Gung Memorial Hospital; Kaohsiung Medical... and other collaborators

Not yet recruiting

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

Chemotherapy | Metastatic Gastric Adenocarcinoma | Second Line
Tianjin Medical University Cancer Institute and...

Recruiting

Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

China
Eli Lilly and Company

Completed

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Carcinoma of Urinary Tract | Urethral Carcinoma | Carcinoma of Ureter | Carcinoma of Renal Pelvis

United States, Canada
Eli Lilly and Company

Completed

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

Renal Cell Carcinoma | Non-Small Cell Lung Cancer | Gastric Adenocarcinoma | Advanced Cancer | Hepatocellular Cancer | Gastroesophageal Junction Adenocarcinoma

United States
Eli Lilly and Company

Completed

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Colorectal Cancer | Mantle Cell Lymphoma | Advanced Cancer

United States, France, United Kingdom
Yonsei University

Active, not recruiting

Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)

Recurrent/Metastatic Gastric Cancer

Korea, Republic of
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)

Hepatocellular Carcinoma

Italy, United States, Spain, China, Korea, Republic of, Taiwan, France, Japan, Germany, Belgium, Austria, Brazil, Czechia, Canada, Poland, United Kingdom, Israel, Australia, Hong Kong, Switzerland
Eli Lilly and Company

Completed

A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer

Gastric Cancer

Japan
Eli Lilly and Company

Completed

A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy

Non-Small Cell Lung Cancer

United States, Germany, Israel, Italy, Mexico, France, Poland, Romania, Spain, Taiwan, United Kingdom, Hungary, Austria, Argentina, Korea, Republic of, Greece, Turkey, India, Netherlands, Russian Federation, Canada, Norway, Sweden, Br... and more
Washington University School of Medicine
Eli Lilly and Company; ImmunityBio, Inc.

Withdrawn

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Carcinoma
Eli Lilly and Company

Active, not recruiting

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Metastatic Cancer | Advanced Cancer | Biliary Tract Cancer

United States, Belgium, Spain, Australia, Czechia, Denmark, Korea, Republic of, Taiwan, Germany, Turkey, France, United Kingdom, Austria, Russian Federation, Mexico, Hungary, Argentina, Sweden
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Eli Lilly and Company

Completed

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States, Germany, Poland, Belgium, Canada, United Kingdom
SCRI Development Innovations, LLC
Celgene

Completed

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Gastroesophageal Cancer

United States
Eli Lilly and Company

Completed

Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy

Cancer

United States

Search clinical trials for: Ramucirumab - IV

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations